Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax is showing positive signs of growth, with its promising vaccine technology and strong partnerships with other companies like Sanofi and Pfizer. The company's focus on preventative measures for a wide range of diseases highlights its potential for long-term success in the industry. Additionally, the recent deals and significant milestone payments from Pfizer further demonstrate the value and potential of Novavax's products. Although there are risks involved in the competitive vaccine market, Novavax's strong market share projections and solid financial performance make it a promising investment opportunity.

Bears say

Novavax is a commercial-stage vaccine company with its own in-house R&D business and partnerships with Sanofi and other companies. However, concerns about a declining U.S. COVID-19 vaccine market and a potentially differentiated tolerability profile for Nuvaxovid could impact the company's future revenues and profits. In addition, there are potential risks to the downside, including failure to successfully develop a combo vaccine and negative regulatory developments. These factors contribute to a negative outlook on Novavax's stock.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.